The Effect of the Health Belief Model-Based Education Given to Mothers of Children Aged 9-15 on HPV Knowledge Level and Child Vaccination

March 1, 2026 updated by: Yildiz Usca, University of Gaziantep

The Effect of Health Belief Model-Based Education on Mothers of Children Aged 9-15 Years: Impact on HPV Knowledge Level and Child Vaccination

This study aims to examine the effects of education provided to mothers of children aged 9-15 within the framework of the Health Belief Model on mothers' knowledge, attitudes, and behaviors about Human Papillomavirus (HPV), and their willingness to have their children vaccinated against HPV. The study, designed with a randomized controlled experimental design, will be conducted at three different Family Health Centers in Gaziantep and will consist of both experimental and control groups. Mothers in the experimental group will receive a three-session visually supported education program prepared by Yıldız USCA, while the control group will receive routine information using HPV brochures from the Ministry of Health. Data collection tools include a personal information form, an HPV knowledge scale, and an HPV Health Belief Model scale.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Literate and able to understand and speak Turkish
  • Mother of a child aged 9-15 years
  • Did not receive any HPV-related education in the past 6 months
  • Has not had HPV vaccination previously
  • Willing to participate voluntarily

Exclusion Criteria:

  • Presence of serious physical or cognitive impairment preventing participation
  • Refusal to provide informed consent
  • Already vaccinated against HPV
  • Already received HPV-related education within the last 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: FAMILY HEALTH CENTER NO. 19
Behavioral: HEALTH BELİEF MODEL
In social psychology, the health belief model (HBM) is a psychological framework used to explain and predict individuals' potentially detrimental behaviors, attitudes and beliefs on their health. Developed in the 1950s by social psychologists at the United States Public Health Service, the model examines how perceptions of susceptibility to illness, the severity of health conditions, the benefits of preventive care, and barriers to healthcare influence behavior. The HBM is widely used in health behavior research and public health interventions to understand and promote engagement in health-protective behaviors
Experimental: FAMILY HEALTH CENTER NO. 31
Behavioral: HEALTH BELİEF MODEL
In social psychology, the health belief model (HBM) is a psychological framework used to explain and predict individuals' potentially detrimental behaviors, attitudes and beliefs on their health. Developed in the 1950s by social psychologists at the United States Public Health Service, the model examines how perceptions of susceptibility to illness, the severity of health conditions, the benefits of preventive care, and barriers to healthcare influence behavior. The HBM is widely used in health behavior research and public health interventions to understand and promote engagement in health-protective behaviors
Experimental: BURAK FAMILY HEALTH CENTER
Behavioral: HEALTH BELİEF MODEL
In social psychology, the health belief model (HBM) is a psychological framework used to explain and predict individuals' potentially detrimental behaviors, attitudes and beliefs on their health. Developed in the 1950s by social psychologists at the United States Public Health Service, the model examines how perceptions of susceptibility to illness, the severity of health conditions, the benefits of preventive care, and barriers to healthcare influence behavior. The HBM is widely used in health behavior research and public health interventions to understand and promote engagement in health-protective behaviors
Placebo Comparator: BURAK FAMILY HEALTH CENTER- control grup
Behavioral: HEALTH BELİEF MODEL
In social psychology, the health belief model (HBM) is a psychological framework used to explain and predict individuals' potentially detrimental behaviors, attitudes and beliefs on their health. Developed in the 1950s by social psychologists at the United States Public Health Service, the model examines how perceptions of susceptibility to illness, the severity of health conditions, the benefits of preventive care, and barriers to healthcare influence behavior. The HBM is widely used in health behavior research and public health interventions to understand and promote engagement in health-protective behaviors
Placebo Comparator: FAMILY HEALTH CENTER NO. 19- control grup
Behavioral: HEALTH BELİEF MODEL
In social psychology, the health belief model (HBM) is a psychological framework used to explain and predict individuals' potentially detrimental behaviors, attitudes and beliefs on their health. Developed in the 1950s by social psychologists at the United States Public Health Service, the model examines how perceptions of susceptibility to illness, the severity of health conditions, the benefits of preventive care, and barriers to healthcare influence behavior. The HBM is widely used in health behavior research and public health interventions to understand and promote engagement in health-protective behaviors
Placebo Comparator: FAMILY HEALTH CENTER NO. 31- control grup
Behavioral: HEALTH BELİEF MODEL
In social psychology, the health belief model (HBM) is a psychological framework used to explain and predict individuals' potentially detrimental behaviors, attitudes and beliefs on their health. Developed in the 1950s by social psychologists at the United States Public Health Service, the model examines how perceptions of susceptibility to illness, the severity of health conditions, the benefits of preventive care, and barriers to healthcare influence behavior. The HBM is widely used in health behavior research and public health interventions to understand and promote engagement in health-protective behaviors

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in HPV Knowledge Score
Time Frame: 1 month after the education program
Health Belief Model Scale(HPVA-SIM): The scale consists of 14 items and four sub-dimensions: perceived benefit (Items 1-3), perceived sensitivity (Items 4-5), perceived seriousness (Items 6-9), and perceived barrier (Items 10-14). The Cronbach Alpha reliability coefficient was calculated as .78 for perceived benefit, .72 for perceived sensitivity, .78 for perceived severity, and .71 for perceived barrier in the sub-dimensions of the scale http://dx.doi.org/10.1016 HPV Knowledge Scale (HPV-KÖ): The HPV-KÖ includes three sub-dimensions of 29 items.Factor 1: General HPV knowledge, Factor 2: Knowledge of HPV screening tests, Factor 3: General HPV vaccine knowledge, Factor 4: Knowledge of the current HPV vaccination program. The Cronbach α value for the 29 items of the original scale was reported as 0.83, and the consistency of the scale was reported to be high for this value doi.org/10.4274/jtgga.galenos.2023.2022-10-9
1 month after the education program

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Gaziantep

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 25, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 1, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 5, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 5, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 1, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Other Identifier (Other Identifier: 2025-76)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings